Sister to Juno's liso-cel, JW's relma-cel lands second-ever CAR-T approval in China
Juno may have stumbled its way to a distant third finish in the CD19 CAR-T race, but its joint venture in China is heading off to a thriving start.
JW Therapeutics, which took its name from co-founders Juno and WuXi AppTec, has scored the second-ever CAR-T approval by China’s National Medical Product Administration just weeks after Fosun Kite, another joint venture, claimed first.
Now sanctioned to treat relapsed or refractory large B-cell lymphoma patients who’ve had two or more lines of systemic therapy, relma-cel was developed on the same cell process platform that spawned Juno’s liso-cel — now Bristol Myers Squibb’s Breyanzi — but a different drug in that it’s tailored for Chinese needs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.